chemyo retatrutide (sodium salt) (LY3437943) Retatrutide - NextChems

The most expensive, most marketed supplement cannot replace the basics

Clinical trial data from Eli Lillys Phase 2 study showed that the 12mg weekly dose produced an average weight loss of 24.2% over 48 weeks, with over 80% of participants losing at least 15% of their starting body weight

People taking GLP-1 receptor agonists may become dehydrated from vomiting or diarrhea, causing kidney problems

DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability